Clinical Study to Evaluate Tolerability and Safety of ARK-E021 Foam and to Monitor Clinical Effect in Acne Vulgaris Patients
Phase 1
Completed
- Conditions
- Acne Vulgaris
- Interventions
- Drug: PlaceboDrug: ARK-E021 5%Drug: ARK-E021 10%
- First Posted Date
- 2011-12-16
- Last Posted Date
- 2013-12-03
- Lead Sponsor
- M. Arkin 1999 Ltd.
- Target Recruit Count
- 157
- Registration Number
- NCT01494285
- Locations
- 🇮🇱
HaEmek Medical Center, Afula, Israel
🇮🇱Meir Medical Center, Kfar Saba, Israel
🇮🇱Souraski Medical Center, Tel Aviv, Israel